Last updated: November 6, 2026
Metozolv ODT is the branded orally disintegrating formulation of metoclopramide hydrochloride, marketed for adults with symptomatic, documented gastroesophageal reflux disease and acute or recurrent diabetic gastroparesis. Its commercial potential has been constrained by metoclopramide’s boxed warning for tardive dyskinesia, treatment-duration limits, generic competition, and the availability of lower-cost conventional tablets and injectable products. Standalone current revenue is not publicly disclosed, but the product’s financial trajectory is consistent with a mature, low-growth specialty product that lost pricing power after generic and alternative-formulation competition.
What is Metozolv ODT and who marketed it?
Metozolv ODT contains metoclopramide hydrochloride in 5 mg and 10 mg orally disintegrating tablets. The dosage form is designed to dissolve on the tongue without water, providing a convenience advantage over standard tablets for patients with nausea, delayed gastric emptying, or difficulty swallowing.
| Attribute |
Metozolv ODT |
| Active ingredient |
Metoclopramide hydrochloride |
| Dosage form |
Orally disintegrating tablet |
| Strengths |
5 mg and 10 mg |
| FDA application |
NDA 022252 |
| Initial sponsor |
Salix Pharmaceuticals |
| Principal indications |
Symptomatic GERD; diabetic gastroparesis |
| FDA regulatory category |
Small-molecule prescription drug |
| Biosimilar exposure |
None |
| Primary commercial substitutes |
Generic metoclopramide tablets, oral solution, and injection |
| Principal safety restriction |
Boxed warning for tardive dyskinesia |
| Commercial positioning |
Convenience formulation rather than a new active ingredient |
The product was associated with Salix Pharmaceuticals and later became part of the Valeant Pharmaceuticals, now Bausch Health, portfolio after Valeant acquired Salix in 2015. Salix’s portfolio included gastrointestinal products with materially different commercial profiles, including Xifaxan, Apriso, Lialda, and Uceris. Metozolv ODT was a smaller product within that portfolio rather than a principal revenue driver (Valeant Pharmaceuticals International, 2015).
When was Metozolv ODT approved by the FDA?
The FDA approved Metozolv ODT under NDA 022252 in 2010. The product approval was based on the known pharmacology and clinical use of metoclopramide, combined with the orally disintegrating delivery system. It did not create new composition-of-matter exclusivity for metoclopramide.
The FDA label limits treatment duration because the risk of tardive dyskinesia increases with cumulative exposure. The label states that treatment should generally not exceed 12 weeks except in rare cases where the therapeutic benefit outweighs the risk. That restriction limits refill frequency and reduces the potential for chronic-use revenue (U.S. Food and Drug Administration, 2011).
What FDA warning affects Metozolv ODT demand?
The boxed warning for tardive dyskinesia is the central regulatory constraint. The risk is associated with prolonged use and cumulative dosage. Other relevant risks include extrapyramidal symptoms, neuroleptic malignant syndrome, depression, hypertension, fluid retention, and drug interactions.
The warning affects market behavior in four ways:
- Physicians may reserve metoclopramide for short-term or refractory use.
- Patients requiring chronic symptom control may be moved to other therapies.
- Payers have limited incentive to reimburse a premium for an orally disintegrating version of an inexpensive generic drug.
- Long-term prescription volume is capped by the product label.
What patents protect Metozolv ODT?
Metozolv ODT did not receive the economic protection associated with a new chemical entity. Metoclopramide is an old active pharmaceutical ingredient, and its core composition-of-matter protection expired decades before the product’s launch.
The commercial protection for Metozolv ODT was therefore expected to depend on formulation, manufacturing, and regulatory exclusivity rather than the active ingredient.
| Protection type |
Relevance to Metozolv ODT |
| New chemical entity patent |
No meaningful protection for the mature metoclopramide molecule |
| Composition-of-matter patent |
Expired before Metozolv ODT launch |
| Formulation patent |
Potentially relevant to the orally disintegrating dosage form |
| Manufacturing patent |
Potentially relevant to tablet manufacture and excipient processing |
| Method-of-use patent |
Limited value because the indications were established uses of metoclopramide |
| FDA approval exclusivity |
Limited compared with a new chemical entity |
| Orange Book leverage |
Dependent on any listed formulation or method patents |
A formulation patent can delay direct substitution only if it is listed in the FDA Orange Book, remains unexpired, and is legally enforceable against an ANDA applicant. Even then, the protection usually covers the specified formulation or method rather than all metoclopramide products.
The Orange Book should be treated as the controlling source for current patent listings, product marketing status, and any active reference-listed-drug information. The commercial record does not indicate that Metozolv ODT retained a broad, durable patent barrier comparable with protected specialty products (U.S. Food and Drug Administration, 2024a).
When does Metozolv ODT lose exclusivity?
Metozolv ODT’s meaningful market exclusivity was limited because the product used an old active ingredient and had no new chemical entity exclusivity period. Any commercial protection came from the NDA approval, formulation differentiation, possible listed patents, and brand-prescribing habits.
The relevant exclusivity timeline is:
| Event |
Approximate timing |
Commercial consequence |
| Metoclopramide active ingredient becomes generic |
Before Metozolv ODT launch |
No molecule-level barrier |
| Metozolv ODT FDA approval |
2010 |
Launch of branded ODT formulation |
| Salix acquisition by Valeant |
2015 |
Portfolio ownership changes |
| Generic and alternative metoclopramide competition |
Post-launch period |
Reduced pricing power |
| Mature product phase |
2020s |
Low-growth or declining brand economics |
There is no commercially meaningful “loss of exclusivity” date comparable with the expiration of a modern branded drug’s composition patent. The product’s economic exclusivity was gradual and formulation-based. Once generic manufacturers could offer acceptable metoclopramide alternatives, the premium for the ODT presentation became difficult to sustain.
Are there Paragraph IV challenges to Metozolv ODT?
Publicly available market information does not establish a major, high-value Paragraph IV litigation campaign comparable with the challenges directed at blockbuster drugs. That outcome is commercially logical. A Paragraph IV challenge is most attractive when the reference product has substantial sales and a durable patent barrier. Metozolv ODT’s small-molecule active ingredient was already generic, and the ODT formulation represented a narrower opportunity.
An ANDA applicant could challenge any listed formulation or method patent through a Paragraph IV certification. The economic value of such litigation would depend on:
- Annual branded sales at the time of challenge.
- The number of active Orange Book patents.
- The probability that the formulation claims would survive invalidity and non-infringement defenses.
- The ability of the generic manufacturer to substitute for the ODT product.
- Whether the generic product would be therapeutically and pharmaceutically equivalent.
The absence of high-profile litigation suggests that the main competitive pressure came from ordinary generic availability and therapeutic substitution rather than a major patent confrontation.
How strong is the Metozolv ODT patent estate?
The patent estate is weak to moderate from a commercial perspective and weak from a molecule-level perspective.
Strengths
The ODT presentation can provide limited differentiation in patients who have swallowing difficulty or need medication without water. A formulation patent, if valid and enforceable, could create a temporary barrier against an identical ODT product.
The reference-listed-drug status also gives the product a regulatory anchor for ANDA applicants seeking approval of an equivalent formulation.
Weaknesses
The active ingredient is old and widely available. Conventional metoclopramide tablets, oral solutions, and injections provide multiple substitution pathways. The safety warning limits chronic use, reducing the value of brand loyalty and long-term adherence programs.
A generic manufacturer does not necessarily need to reproduce every commercial attribute of the branded ODT. It can compete through conventional tablets, lower pricing, hospital contracting, or alternative liquid formulations.
What formulations compete with Metozolv ODT?
Metozolv ODT competes in a broad metoclopramide market rather than in a protected standalone franchise.
| Competitive product |
Competitive effect |
| Generic metoclopramide tablets |
Direct price substitute for many patients |
| Generic metoclopramide oral solution |
Useful for swallowing difficulty and dose flexibility |
| Metoclopramide injection |
Used in hospitals and acute-care settings |
| Domperidone, where accessible |
Alternative prokinetic, subject to jurisdictional restrictions |
| Erythromycin |
Used in selected gastroparesis settings, limited by tachyphylaxis and tolerability |
| Other antiemetics |
Compete for nausea control but may not replicate prokinetic activity |
| Dietary and procedural management |
Reduce reliance on chronic pharmacologic treatment |
The ODT format is commercially valuable only when the patient or prescriber places a material value on convenience. That value is generally insufficient to offset a substantial price gap against generic tablets.
What was the financial trajectory for Metozolv ODT?
Metozolv ODT’s standalone revenue has not been separately disclosed in the public financial reporting of its owners. Salix and Valeant reported portfolio-level results, while later Bausch Health disclosures emphasized major brands and business segments rather than providing a detailed Metozolv ODT revenue series.
The product’s likely financial trajectory can be summarized as follows:
- Launch phase: revenue depended on branded prescribing, ODT convenience, and limited competition.
- Expansion phase: growth was constrained by the narrow approved use, the boxed warning, and competition from inexpensive metoclopramide products.
- Mature phase: price erosion and substitution reduced the product’s contribution.
- Portfolio phase: the product became a minor asset relative to larger gastrointestinal brands.
- Late commercial phase: the financial value shifted from growth to residual cash flow, manufacturing continuity, and portfolio rationalization.
The largest value drivers were likely net price, payer coverage, generic availability, sales-force allocation, and the cost of maintaining a separate ODT supply chain. A product with modest unit volume can remain profitable if manufacturing costs are low and promotional spending is minimal. Conversely, the economics deteriorate quickly when a specialized formulation requires separate production, packaging, quality testing, and inventory management.
What revenue exposure does Metozolv ODT create for Bausch Health?
Metozolv ODT is unlikely to create material consolidated revenue exposure for Bausch Health. The company’s larger gastrointestinal assets have historically driven the commercial performance of the segment. Metozolv ODT’s strategic relevance is more likely to involve portfolio completeness and residual sales than a material effect on enterprise valuation.
The main financial risks are:
- Continued generic price erosion.
- Product discontinuation or limited availability.
- Loss of pharmacy stocking priority.
- Manufacturing costs that exceed net sales contribution.
- Reduced physician use because of the boxed warning.
- Substitution by lower-cost conventional metoclopramide products.
The main upside is limited. It would depend on a supply disruption affecting generic competitors, a niche reimbursement opportunity, or a successful repositioning for patients needing an orally disintegrating product. None of these factors creates a durable growth thesis without stronger market-access evidence.
What generic launch scenarios exist for Metozolv ODT?
Scenario 1: Direct ODT generic substitution
A generic manufacturer launches an equivalent 5 mg and 10 mg orally disintegrating tablet. This scenario produces the greatest pressure on brand price and volume because it directly replicates the product’s primary differentiation.
Scenario 2: Formulation-adjacent substitution
Generic tablets or oral solutions gain share without a directly equivalent ODT. This can still reduce Metozolv ODT demand because physicians and pharmacists may accept a different dosage form when cost is the primary consideration.
Scenario 3: Limited generic availability
If few manufacturers maintain the ODT presentation, the brand may retain a narrow convenience niche. The product would still face pricing pressure from conventional metoclopramide and would remain exposed to the FDA safety restrictions.
Scenario 4: Brand withdrawal
If net sales fall below the cost of maintaining the product, the owner may discontinue commercial supply. Patients would likely transition to generic tablets, oral solution, or other antiemetic and prokinetic therapies.
What patent litigation and settlement risks affect Metozolv ODT?
The litigation risk is limited relative to high-value branded drugs. The key legal issues would be formulation claim scope, bioequivalence, excipient differences, tablet disintegration characteristics, and whether an ANDA product infringes any listed patent.
A settlement could include a delayed generic launch, license terms, or a manufacturing arrangement. However, the commercial incentive for a large reverse-payment settlement would be low if branded sales were modest and the patent estate narrow. Any settlement analysis should be based on actual Orange Book listings, ANDA litigation records, and the specific claims asserted rather than on the existence of the brand alone.
How does Metozolv ODT compare with other gastrointestinal drugs?
Metozolv ODT has a weaker commercial and patent profile than newer gastrointestinal brands such as rifaximin products or protected acid-suppression formulations.
| Factor |
Metozolv ODT |
Protected specialty GI drug |
| Active ingredient age |
Old |
Often newer or reformulated |
| Molecule patent protection |
None of practical value |
Often significant |
| Formulation differentiation |
ODT convenience |
May include delivery or release technology |
| Chronic-use potential |
Limited by boxed warning |
Often higher |
| Generic substitution |
High |
Usually delayed |
| Pricing power |
Low to moderate |
Moderate to high during exclusivity |
| Revenue durability |
Limited |
Potentially substantial |
| Biosimilar risk |
None |
Relevant only for biologic comparators |
What is the investment and licensing assessment for Metozolv ODT?
Metozolv ODT is a low-growth, low-barrier product. It is more suitable for a portfolio optimization or niche generic strategy than for a premium licensing transaction based on patent exclusivity.
A buyer would focus on:
- Verified net sales and prescription volume.
- Current wholesale acquisition cost and net price.
- Product availability and back orders.
- Manufacturing cost per tablet.
- Active Orange Book patents.
- Current generic competition.
- Pharmacovigilance obligations.
- Reimbursement by commercial and government payers.
- Remaining commercial life.
The product could have value in a broader gastrointestinal portfolio with shared sales, distribution, and manufacturing infrastructure. Its standalone value is limited because the active ingredient is generic, the clinical label restricts duration, and the ODT advantage is narrow.
Key Takeaways
- Metozolv ODT is a branded 5 mg and 10 mg orally disintegrating formulation of generic metoclopramide.
- FDA approval occurred in 2010 under NDA 022252.
- The product has no meaningful new chemical entity protection.
- Its commercial protection depended on formulation differentiation, possible listed patents, and brand positioning.
- The boxed warning for tardive dyskinesia limits chronic use and reduces market size.
- Generic tablets, oral solution, and injectable metoclopramide create substantial substitution pressure.
- Public filings do not disclose a reliable standalone revenue series for Metozolv ODT.
- The product is unlikely to represent material revenue exposure for Bausch Health.
- Paragraph IV litigation and settlement value appear limited relative to blockbuster gastrointestinal products.
- The most probable financial trajectory is mature or declining revenue, with residual niche demand tied to the ODT presentation.
FAQs
Is Metozolv ODT still commercially available?
Availability depends on current manufacturer supply, pharmacy inventory, and the FDA drug database. The branded product’s commercial presence is materially less important than the broader generic metoclopramide market.
Does Metozolv ODT have a new chemical entity exclusivity period?
No. Metoclopramide was an established active ingredient before Metozolv ODT was approved. The product’s differentiation came from the dosage form.
Can generic metoclopramide tablets replace Metozolv ODT?
In many clinical situations, physicians can use generic metoclopramide tablets or oral solution. The appropriate substitute depends on the prescription, patient swallowing ability, dose, and clinical judgment.
Is Metozolv ODT exposed to biosimilar competition?
No. Metozolv ODT is a small-molecule drug. Its competitive exposure comes from generic drugs and therapeutic alternatives, not biosimilars.
What is the most important diligence item for a Metozolv ODT acquisition?
The most important item is verified current net sales by product and dosage form, followed by confirmation of active Orange Book listings, generic competition, supply status, and manufacturing cost.
References
- Bausch Health Companies Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.bauschhealth.com
- Salix Pharmaceuticals, Ltd. (2015). Salix Pharmaceuticals, Ltd. reports annual results and corporate developments. https://www.salix.com
- U.S. Food and Drug Administration. (2011). Metozolv ODT prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
